Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CD123-Targeted CAR-T for Relapsed/Refractory AML
NCT04272125Phase 2Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute myeloid leukemia (AML), sponsored by Chongqing Precision Biotech. Primary endpoints: Adverse events related to treatment at 2 years and Response rate of CD123 CAR-T treatment at 6 months. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04272125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272125.